175 related articles for article (PubMed ID: 26432753)
1. Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237).
Goos JACM; Verbeek J; Geldof AA; Hiemstra AC; van de Wiel MA; Adamzek KA; Delis-Van Diemen PM; Stroud SG; Bradley DP; Meijer GA; Hoekstra OS; Fijneman RJA; Windhorst AD
Nucl Med Biol; 2016 Jan; 43(1):63-72. PubMed ID: 26432753
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W
Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P
Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Manfredi MG; Ecsedy JA; Chakravarty A; Silverman L; Zhang M; Hoar KM; Stroud SG; Chen W; Shinde V; Huck JJ; Wysong DR; Janowick DA; Hyer ML; Leroy PJ; Gershman RE; Silva MD; Germanos MS; Bolen JB; Claiborne CF; Sells TB
Clin Cancer Res; 2011 Dec; 17(24):7614-24. PubMed ID: 22016509
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.
Wang L; Arras J; Katsha A; Hamdan S; Belkhiri A; Ecsedy J; El-Rifai W
Mol Oncol; 2017 Aug; 11(8):981-995. PubMed ID: 28417568
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
[TBL] [Abstract][Full Text] [Related]
7. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.
Kurokawa C; Geekiyanage H; Allen C; Iankov I; Schroeder M; Carlson B; Bakken K; Sarkaria J; Ecsedy JA; D'Assoro A; Friday B; Galanis E
J Neurooncol; 2017 Jan; 131(1):41-48. PubMed ID: 27816996
[TBL] [Abstract][Full Text] [Related]
8. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
[TBL] [Abstract][Full Text] [Related]
10. Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells.
Inchanalkar S; Deshpande NU; Kasherwal V; Jayakannan M; Balasubramanian N
Mol Pharm; 2018 Aug; 15(8):3046-3059. PubMed ID: 29863884
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
[No Abstract] [Full Text] [Related]
12. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
13. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.
Durlacher CT; Li ZL; Chen XW; He ZX; Zhou SF
Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):585-601. PubMed ID: 26999067
[TBL] [Abstract][Full Text] [Related]
14. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
Do TV; Xiao F; Bickel LE; Klein-Szanto AJ; Pathak HB; Hua X; Howe C; O'Brien SW; Maglaty M; Ecsedy JA; Litwin S; Golemis EA; Schilder RJ; Godwin AK; Connolly DC
Oncogene; 2014 Jan; 33(5):539-49. PubMed ID: 23334327
[TBL] [Abstract][Full Text] [Related]
15. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
[TBL] [Abstract][Full Text] [Related]
16. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.
Wetmore C; Boyett J; Li S; Lin T; Bendel A; Gajjar A; Orr BA
Neuro Oncol; 2015 Jun; 17(6):882-8. PubMed ID: 25688119
[TBL] [Abstract][Full Text] [Related]
17. Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.
Goff LW; Azad NS; Stein S; Whisenant JG; Koyama T; Vaishampayan U; Hochster H; Connolly R; Weise A; LoRusso PM; Salaria SN; El-Rifai W; Berlin JD
Invest New Drugs; 2019 Apr; 37(2):315-322. PubMed ID: 30191522
[TBL] [Abstract][Full Text] [Related]
18. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
[TBL] [Abstract][Full Text] [Related]
19. The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells.
Zumbar CT; Usubalieva A; King PD; Li X; Mifsud CS; Dalton HM; Sak M; Urio S; Bryant WM; McElroy JP; Farmer G; Lehman NL
J Neurooncol; 2018 May; 137(3):481-492. PubMed ID: 29396807
[TBL] [Abstract][Full Text] [Related]
20. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
